FDA Class I Recall Confirms Guberman Warnings: Systemic Accreditation Collapse Endangers Medical Devices, Aerospace, and U.S. Industrial Supply Chains40 Year Quality Expert & Boeing Shareholder, Daryl Guberman Warned Major Manufacturers—including Medtronic, Boston Scientific, Smith & Nephew, and Johnson & Johnson—before The FDA Recall. The GUBERMAN Anomaly-Discovery, Now Exposes The Largest Multi Sector Oversight Failure In Modern U.S. History.
By: GUBERMAN-PMC,LLC On April 27, 2026, Guberman formally notified multiple manufacturers, including Medtronic, Boston Scientific, Smith & Nephew, Johnson & Johnson, Zimmer Biomet, and Stryker, that implantable devices manufactured under the compromised 2018–Present accreditation environment were at risk. "This recall is not an isolated event," Guberman said. "It is the direct result of a systemic accreditation collapse that has contaminated medical devices, aerospace components, pharmaceuticals, and industrial materials." FDA Recall Confirms the Warning The FDA's Class I recall requires urgent in‑person software updates for thousands of implanted devices. The agency confirmed:
Multi‑Year Failure Pattern: ACCOLADE Pacemakers Have Been Failing for Years, Not Just 2026 The 2026 Class I recall is not the first failure involving Boston Scientific's ACCOLADE pacemaker line. FDA records show a three‑year sequence of escalating failures, each involving different root causes — a clear sign of systemic manufacturing and oversight breakdown, not isolated defects. FDA WARNINGS TO BOSTON SCIENTIFIC: 2-Years ACCOLADE Pacemakers 2024 —FDA SAFETY COMMUNICATION Date Issued: December 16, 2024 Title: Accolade Pacemaker Devices by Boston Scientific and Potential Need for Early Device Replacement – FDA Safety Communication Link: https://www.fda.gov/ 2025 — FDA CLASS I RECALL Date Initiated by Firm: August 20, 2025 Title: Class I Device Recall – ACCOLADE Pacemakers Link: https://www.accessdata.fda.gov/ 2026 — FDA CLASS I RECALL / CORRECTION Date Issued: May 2026 Title: Pacemaker Correction: Boston Scientific Issues Correction for ACCOLADE Pacemakers and CRT‑Ps Link: https://www.fda.gov/ This three‑year pattern proves that ACCOLADE failures are not new, not isolated, and not unpredictable — they are the direct result of the 2018–Present accreditation collapse that compromised ISO 13485 oversight across the medical‑device sector. "The FDA recall confirms what I warned manufacturers about on April 27," Guberman said. "These failures were the inevitable outcome of a broken accreditation system." Accreditation Breakdown: 2018–Present Guberman's forensic reports document a collapse inside the ANSI‑ANAB accreditation structure beginning in 2018. This breakdown affected:
Cross‑Sector Impact: Medical, Aerospace, Industrial, and Pharmaceutical The accreditation collapse is not limited to medical devices. It affects: WORLDWIDE FAILURE! :
"Whether it's a pacemaker or a jet engine, the same broken accreditation structure governs both," Guberman emphasized. The GUBERMAN Anomaly: Largest Industrial Oversight Failure in U.S. History The GUBERMAN Anomaly, first documented in 2018, has now expanded into what experts describe as the largest industrial, regulatory, and fiduciary oversight failure in modern U.S. history. https://guberman- Its reach includes:
"These agencies and investors understand the implications," Manufacturers Were Warned Before FDA Action Guberman's April 27 advisory warned that devices manufactured between 2018 and 2026 may contain systemic vulnerabilities due to:
Public‑Health and Legal Exposure The recall requires in‑person updates, meaning:
WARNING: Combined Medical Device ADVISORY And FDA Regulatory Framework Analysis https://www.prlog.org/ Guberman warns that this event may trigger:
Hospitals are not storing these ACCOLADE pacemakers in temperature‑ Lithium‑iodine and lithium‑silver‑
And the failure goes deeper: Hospitals are only required to keep explanted (taken out of the body) pacemakers for a short, preset period — typically 30 days, 60 days, or at most 90 days — because no federal regulation requires long‑term storage. Once that retention window expires, the hospital can legally dispose of the device, even if it may contain evidence of battery defects, seal failures, electrical instability, or manufacturing errors. This means critical proof is often destroyed before patients, families, investigators, or regulators ever have the chance to examine it. In a system already weakened by recalls and accreditation failures, these short expiration limits ensure that the most important evidence disappears. All documents available at: https://guberman- Media Contact DARYL GUBERMAN ***@yahoo.com 203 556 1493 Photos: https://www.prlog.org/ https://www.prlog.org/ https://www.prlog.org/ End
|
Account Phone Number